T-cell Engagers (CD3 Bispecifics)

Cat. No.

AT1188

CAS No.

1664355-28-5

Flotetuzumab

Synonyms: MGD006; S80880

Flotetuzumab (MGD006; S80880) is a bispecific dual-affinity retargeting antibody (DART) that targets CD123 and CD3, designed for the treatment of acute myeloid leukemia (AML). This investigational molecule facilitates T-cell activation by concurrently engaging CD123 on target cells and CD3 on effector T cells. This interaction promotes T-cell-mediated cytotoxicity against the target cells. Efficacy studies, including those using a mouse model with patient-derived xenografts (PDX), have demonstrated flotetuzumab's potential to inhibit the progression of AML.

Cat. No.

AT1231

CAS No.

2599198-83-9

Umizortamig

Umizortamig is a monoclonal antibody engineered to target CD3E, EGFR, TNFRSF9, PD-L1, and CD3G. This multi-specific antibody is designed for the simultaneous modulation of key immune checkpoints and signaling pathways, potentially enhancing therapeutic efficacy in oncology and immunotherapy applications. Umizortamig's ability to bind multiple targets allows for a coordinated approach in the regulation of immune responses, making it a valuable tool for research in cancer biology and immune regulation.

Cat. No.

AT1247

CAS No.

1905409-39-3

Mosunetuzumab

Synonyms: BTCT-4465A

Mosunetuzumab (BTCT-4465A) is a fully humanized, full-length immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody designed to concurrently target CD20 on B cells and CD3 on T cells. This bispecific nature allows Mosunetuzumab to redirect T cells to engage and eliminate malignant B cells. It is primarily utilized in research focused on relapsed or refractory B-cell non-Hodgkin lymphomas (B-NHLs), providing a valuable tool for studies aimed at understanding and potentially treating these conditions.

Cat. No.

AT1261

CAS No.

2134641-34-0

Epcoritamab

Synonyms: GEN3013

Epcoritamab (GEN3013) is a bispecific IgG1 antibody designed to redirect T-cells to target CD3×CD20+ tumor cells. This antibody facilitates potent T-cell-mediated cytotoxicity against B-cell non-Hodgkin lymphoma (NHL) cell lines, offering a targeted approach to cancer immunotherapy.

Cat. No.

AT1271

CAS No.

140608-64-6

Muromonab

Muromonab is a monoclonal antibody that specifically targets the CD3 receptor on T cells. This antibody effectively blocks cytotoxic T cell activity, serving as a potent immunosuppressive agent. It is primarily used to prevent acute rejection in solid organ transplantation by inhibiting the immune response that can lead to organ rejection.

Cat. No.

AT1335

CAS No.

2413453-53-7

Vepsitamab

Synonyms: AMG 199

Vepsitamab (AMG 199) is a bispecific T-cell engager (BiTE) antibody designed for precise dual targeting of CD3 on T cells and MUC17 on tumor cells. This antibody facilitates the redirection of T cell cytotoxic activity towards MUC17-expressing tumor cells, resulting in targeted tumor cell lysis. Additionally, Vepsitamab promotes T cell activation and proliferation, enhancing anti-tumor immune responses. This product is pivotal for research focused on cancer immunotherapy and the molecular mechanisms of T cell-mediated cytotoxicity.

Cat. No.

AT1352

CAS No.

2795115-07-8

Rezetamig

Rezetamig is a monoclonal antibody that targets both CD3E and CD22 molecules. This dual specificity allows for enhanced targeting of immune cells, making it a valuable tool in immunological research and therapeutic applications.

Cat. No.

AT1358

CAS No.

1831098-91-9

Duvortuxizumab

Synonyms: MGD 011

Duvortuxizumab (MGD 011) is a chimeric, humanized immunoglobulin antibody designed for dual targeting of CD19 and CD3E. This bifunctional antibody facilitates the engagement of T cells and B cells, promoting immune-mediated clearance of CD19-expressing cells. It is primarily utilized in research focused on the therapeutic potential in B-cell malignancies and other hematologic disorders.

Cat. No.

AT1363

CAS No.

2314491-93-3

Acapatamab

Synonyms: AMG-160

Acapatamab (AMG-160) is a monoclonal antibody designed to target both CD3E and FOLH1. This dual-targeting biologic is engineered for the potential treatment of various cancers, leveraging its ability to bind to CD3E on T cells and FOLH1 on tumor cells, thereby facilitating a targeted immune response against cancerous tissues. Acapatamab is primarily used in research focused on cancer immunotherapy and the study of bispecific antibody mechanisms.

Cat. No.

AT1412

CAS No.

2278244-14-5

Nivatrotamab

Synonyms: Hu3F8-BsAb

Nivatrotamab (Hu3F8-BsAb) is a humanized bispecific antibody targeting both GD2 and CD3 antigens. This dual specificity enables Nivatrotamab to function as a T-cell engager, facilitating the direct interaction between T-cells and GD2-expressing tumor cells. It is primarily utilized in research focused on neuroblastoma, a cancer that commonly arises from neural crest cells in the adrenal glands and can also develop in nerve tissues throughout the body. Nivatrotamab's mechanism of action and its role in recruiting and activating T-cells against GD2-positive cancer cells make it a valuable tool in immuno-oncology research.

Cat. No.

AT1438

CAS No.

2138442-13-2

Vibecotamab

Synonyms: XmAb14045

Vibecotamab (XmAb14045) is a bispecific antibody designed to target CD123 and CD3, facilitating the selective engagement of T cells and the subsequent targeted elimination of cells expressing CD123. This antibody demonstrates potent antitumor activity, making it particularly valuable for research in acute myeloid leukemia (AML). Vibecotamab's mechanism of action and specificity for CD123-expressing cells underscore its utility in studies aimed at investigating immune-mediated approaches to cancer therapy.

Cat. No.

AT1442

CAS No.

2449199-61-3

Emirodatamab

Synonyms: AMG-427

Emirodatamab is a monoclonal antibody designed to target both CD3E and FLT3. This dual-specificity allows for potential applications in modulating immune responses and targeting FLT3-associated malignancies. Emirodatamab's unique ability to bind these two distinct antigens makes it a valuable tool for research in immunotherapy and hematologic cancers.

Cat. No.

AT1497

CAS No.

2249888-53-5

Cevostamab

Synonyms: BFCR 4350A; RG 6160; RO 7187797

Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based bispecific antibody (BsAb) designed to target the membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells, as well as CD3 on T cells. This dual targeting promotes efficient synapse formation between T cells and MM tumor cells, enhancing the cytotoxic activity of T cells against the tumor cells. Cevostamab's unique mechanism of action makes it a valuable tool for research in immuno-oncology and the therapeutic targeting of multiple myeloma.

Cat. No.

AT1508

CAS No.

881191-44-2

Otelixizumab

Synonyms: ChAglyCD3; TRX 4

Otelixizumab (ChAglyCD3) is a monoclonal antibody targeting the CD3 antigen on human T cells. It is specifically designed for research applications focusing on Type 1 diabetes. This antibody can be instrumental in studies aimed at understanding T cell behavior and the immune response in diabetic pathology.

Cat. No.

AT1559

CAS No.

1442657-12-6

Pasotuxizumab

Synonyms: BAY 2010112; AMG 212

Pasotuxizumab (BAY 2010112) is a bispecific T-cell engager (BiTE) targeting PSMA and CD3, designed for the study of metastatic castration-resistant prostate cancer (mCRPC). This antibody exhibits binding affinities with dissociation constants (K_D) of 9.4 nM for human CD3 and 47.0 nM for PSMA, facilitating its dual specificity. Pasotuxizumab is instrumental in engaging T-cells and directing them towards PSMA-expressing prostate cancer cells, making it a valuable tool for advanced prostate cancer research.